NICE Recommends BMS’s Melanoma Combination Treatment

The UK’s drug pricing watchdog is recommending reimbursement of Bristol-Myers Squibb’s melanoma combination treatment of Opdivo and Yervoy, provided the company discounts the latter.

In a final appraisal, UK’s National Institute for Health and Care Excellence deemed the combination therapy a cost-effective treatment for adults with advanced melanoma compared to its clinically relevant comparator, Merck’s Keytruda.

The appraisal committee found that the combination slowed the progression of melanoma compared to Yervoy and Keytruda, individually. The median progression-free survival was 11.5 months for the combination compared to 2.9 months for Yervoy alone.